Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody that selectively binds and neutralizes a proinflammatory cytokine, interleukin 17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of autoimmune diseases. In rheumatology, secukinumab is primarily used for the treatment of ankylosing spondylitis and psoriatic arthritis, both of which are chronic inflammatory conditions associated with IL-17A-mediated inflammation.

The main indications of secukinumab in rheumatology include:

  • Ankylosing spondylitis: Secukinumab is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately to conventional therapy, such as nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Psoriatic arthritis: Secukinumab is also approved for the treatment of active psoriatic arthritis in adults, including patients who have not responded adequately to previous DMARD therapy.

Secukinumab is administered by subcutaneous injection and dosing frequency varies depending on the specific condition being treated. It has been shown to improve signs and symptoms, inhibit structural damage, and improve physical function in patients with ankylosing spondylitis and psoriatic arthritis. As with other biologic medications, secukinumab may increase the risk of infections and other adverse effects, so its use should be carefully monitored by a rheumatologist or other qualified healthcare provider. Regular monitoring of patients receiving secukinumab may include assessments for signs and symptoms of infection, as well as laboratory monitoring for changes in blood counts and liver function tests.